drugset / Trial / NCT00971802

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

NCT00971802

Phase 1 Completed 50 enrolled Pfizer
RandomizedParallel-groupDouble-blind

Summary

To evaluate the safety and tolerability of PF-03882845 in Healthy Volunteers. To evaluate the pharmacokinetics of PF-03882845 in Healthy Volunteers. To evaluate the pharmacodynamics of PF-03882845 in Healthy Volunteers.

Timeline

Start
2009-09
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03882845 Small molecule 20 mg Oral
Subject PF-03882845 Small molecule 60 mg Oral
Subject PF-03882845 Small molecule 120 mg Oral
Subject PF-03882845 Small molecule 185 mg Oral

Indications

No indication recorded.